Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737187 | 0.84 | IL4I1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL13734906 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL13734590 | 0.75 | HTR2C (0.36) | — | |
| SCHEMBL13734835 | 0.74 | KDM4E (0.37) | KDM4EALDH1A1 | |
| SCHEMBL30947972 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13735025 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13736284 | 0.73 | KDM4E (0.55) | KDM4EALDH1A1 | |
| SCHEMBL13734825 | 0.72 | CNR2 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL13734089 | 0.69 | PTGS2 (0.36) | — | |
| SCHEMBL13434519 | 0.69 | TAAR1 (0.35) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336960-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2935270-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | Novartis AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| WO-2014099880-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| EP-2702063-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | KDM4E 743/4885ALDH1A1 719/4885 |
| US-20150336960-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | PIM1, PIM2, PIM3 | KDM4E 2213/4885ALDH1A1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.